During Thursday’s Current trade, Shares of Scripps Netoperates Interactive, Inc. (NYSE:SNI), gain 2.03% to $53.90.
Scripps Netoperates Interactive, Inc. (SNI) stated second-quarter 2015 operating results.
Merged revenues for the quarter raised $24.0 million, or 3.4 percent, to $732.1 million from the preceding-year period. Results for the three-month period ended June 30 comprise advertising revenue of $502.9 million, up $5.9 million, or 1.2 percent, over last year and associate fee revenue of $215.2 million, up $17.2 million, or 8.7 percent, year over year.
Cost of services and selling, general and administrative expenses for the quarter reduced $15.3 million, or 3.9 percent, to $373.6 million from the preceding-year period, driven by a reduction in ongoing employee costs as a result of the restructuring program executed in the fourth quarter of 2014. Comprised of in the second quarter of 2015 were:
- $5.3 million of costs related to the formerly declared restructuring program; and
- $4.2 million of transaction and integration expenses related to the TVN acquisition.
Comprised of in the second quarter of 2014 were:
- $9.7 million of costs related to the termination of certain third-party service provider contracts.
Not taking into account the impact of these items in their respective periods, cost of services and selling, general and administrative expenses would have reduced $15.1 million, or 4.0 percent, to $364.0 million.
Scripps Netoperates Interactive, Inc. develops lifestyle-oriented content for linear and interactive video platforms in the United States, the United Kingdom and other European markets, the Middle East and Africa, the Asia-Pacific, and Latin America. The company delivers content that focuses on specifically defined topics of interest for audiences and advertisers.
Shares of KBR, Inc. (NYSE:KBR), inclined 1.74% to $17.50, during its current trading session.
KBR, Inc. (KBR) declared that its Board of Directors has declared a quarterly cash dividend of eight cents ($0.08) per share on the Company`s common stock, par value $0.001 per share, to be paid on October 15, 2015 to stockholders of record on September 15, 2015.
KBR, Inc. operates as an engineering, construction, and services company worldwide. The company operates through three segments: Technology & Consulting, Engineering & Construction, and Government Services. The Technology & Consulting segment offers various services and solutions, counting licensing, engineering and design, proprietary equipment, plant automation, catalysts, and related consulting services to hydrocarbons, chemicals, and fertilizer markets.
Myriad Genetics, Inc. (NASDAQ:MYGN), during its Thursday’s current trading session gained 0.41% to $38.98.
Myriad Genetics, Inc. (MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, today announced that it will host an Investor Day in New York City on Sept. 14, 2015.
At the event, members of the Myriad executive management team will discuss the Company’s five-year strategic plan and provide updates on its three strategic imperatives to transition and expand the hereditary cancer market, diversify the product portfolio and increase the international contribution.
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The company’s molecular diagnostic tests are designed to analyze genes expression levels, and proteins to assess an individual’s risk for developing disease later in life; diagnose diseases and determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. It offers various molecular diagnostic tests, counting myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; BRACAnalysis and BART, sequencing tests for hereditary breast and ovarian cancer; BRACAnalysis CDx sequencing test for use as a companion diagnostic in identifying ovarian cancer patients with deleterious suspected deleterious germline; and Tumor BRACAnalysis CDx sequencing test used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors.
Finally, TESARO Inc (NASDAQ:TSRO), gained 2.30%, to $54.63.
TESARO, Inc. (TSRO), an oncology-focused biopharmaceutical company, recently stated operating results for second-quarter 2015 and offered an update on the Company’s development programs.
Recent Business Highlights
- The New Drug Application (NDA) for oral rolapitant is under review by the U.S. Food and Drug Administration (FDA), with a PDUFA aim date of September 5, 2015.
- Commercial preparations are well underway in support of a potential oral rolapitant product launch in the fourth quarter of 2015.
- The rolapitant bioequivalence trial successfully achieved its primary endpoint, demonstrating similar exposure for a dose of intravenous (IV) rolapitant as contrast to a dose of oral rolapitant.
- Expansion of the TESARO commercial organization is ongoing, with sales administration, medical science liaison, and nurse educator teams now in place and the build-out of the field sales team is nearly complete in preparation for launch.
- TESARO and Jiangsu Hengrui Medicine Co., Ltd. declared an exclusive license agreement for the development, registration, manufacture, and commercialization of rolapitant in China.
- Phase 3 data from the NOVA trial of niraparib for patients with high-grade serous, platinum-sensitive, relapsed ovarian cancer is predictable in the fourth quarter of 2015, following completion of enrollment in both cohorts earlier this year.
TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio comprise of Rolapitant, a neurokinin-1 receptor antagonist, which has accomplished phase 3 oral formulation trials, in addition to is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that is in phase 3 clinical trials to treat ovarian cancer; and TSR-011, an orally accessible anaplastic lymphoma kinase inhibitor, which is in phase 1/2a dose escalation clinical trial in cancer patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
